Invitae Corporation (NYSE: NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced that it has signed exchange and financing agreements with a fund managed by Deerfield Management C
Gainers
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Financial Guidance
On a pro forma basis, the company exited fourth quarter 2022 at an annualized revenue of approximately $450 million for its remaining business. Management is expecting 2023
Shares of Invitae Corp (NYSE: NVTA) came under pressure on Monday, after gaining more than 24% in January.
Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs.
Over the past three months, shares of Invitae Inc. (NYSE:NVTA) moved lower by 13.23%. Before having a look at the importance of debt, let's look at how much debt Invitae has.